SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 2193370

Cover Image

PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 2193370

MRNA Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035

PUBLISHED:
PAGES: 194 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 4850
PDF & Excel (Multi User License)
USD 6050
PDF & Excel (Enterprise User License)
USD 8350

Add to Cart

The mRNA Therapeutics Market reached USD 6.19 billion in 2025 and is projected to grow at an 11.3% CAGR from 2026 to 2035. The market is expected to cross USD 15.3 billion valuation by 2035. Approved vaccines provide the current commercial base, while development-stage products contribute only through anticipated authorization. Seasonal respiratory demand increasingly replaces emergency procurement. Regulatory milestones, payment decisions, and manufacturing readiness influence the transition toward a broader modality that may require different distribution, diagnostic, and care arrangements for specialized therapeutic applications.

Market Scope
Start Year2025
Forecast Year2026-2035
Start Value$6.19 Billion
Forecast Value$15.3 Billion
CAGR11.3%

Personalized oncology development creates a commercial model involving tumor sequencing, rapid manufacturing, treatment coordination, and delivery through specialist centers. Clinical validation matters because it supports the feasibility of this linked process, rather than product efficacy alone. Preparedness investment offers another source of continuity outside routine commercial demand. Multilateral programs can retain development and production resources for infectious-disease applications beyond established respiratory products. Lipid nanoparticle engineering also influences reach through improved temperature tolerance, tissue targeting, and alternative delivery routes. These changes may reduce distribution barriers and support repeated outpatient use. Commercial opportunity therefore depends on converting technical progress into scalable operations, with manufacturing turnaround, site capability, and payer authorization determining whether specialized programs become repeatable therapeutic services.

Based on product, Comirnaty generated USD 4.36B in 2025. Its vaccination footprint provides an established commercial foundation as purchasing becomes seasonal. Continuing demand depends on reformulation, access through pharmacies and other channels, and relevance within endemic immunization. Broader platform development creates a different operating environment from emergency supply. Commercial resources must support recurring individual and institutional decisions rather than broad public procurement alone. Coordination with BioNTech's oncology pipeline also influences the franchise's longer-term position. The segment therefore combines an established respiratory base with the challenge of maintaining usable distribution and customer confidence as new indications alter the wider mix of approved products and specialized applications.

By application, COVID-19 prevention is expected to generate USD 5.70B in 2035. Demand provides an endemic commercial floor under a purchasing model different from emergency vaccination. Higher-risk populations and channels that can support seasonal uptake become more important. Reformulation and provider confidence influence continuing participation, while practical access affects whether patient interest leads to administration. Commercial demand therefore depends on execution within recurring care and retail arrangements. Suppliers need usable distribution and appropriate engagement rather than rely on population-wide mandates. The application remains significant to the operating market, connecting a mature vaccine base with the evolving decisions through which patients, providers, and institutions maintain seasonal protection.

The North America mRNA therapeutics market is projected to generate USD 7.03B by 2035. Established COVID-19 and RSV demand combines with advanced oncology infrastructure. Developed reimbursement channels support the evaluation of specialized products. The United States influences regulatory precedent, pricing, and launch design, making its commercial pathways relevant to broader platform development. Regional opportunity therefore extends beyond distribution of existing respiratory vaccines. Suppliers need to connect authorization and payment with manufacturing and provider readiness as therapeutic applications evolve. The region's institutions provide resources for this more complex model, but adoption still depends on whether new products can operate within actual diagnostic, treatment, and purchasing pathways rather than remain technically promising development programs.

Pfizer/BioNTech held over 70.6% market share in 2025. Comirnaty's global reach supports an established commercial position, while BioNTech's oncology development offers potential extension beyond respiratory vaccination. Regulatory and supply-chain experience provide useful resources as indications diversify. The partnership's commercial challenge involves maintaining relevance within mature COVID-19 demand while preparing for different therapeutic requirements. Customers in specialized settings will need support that differs from conventional vaccine distribution. Its position connects a substantial existing footprint with pipeline opportunities, where successful development must translate into qualified manufacturing, payer engagement, and provider integration to establish repeatable use within new care pathways rather than rely on platform familiarity alone.

Some of the major players in this market are Moderna, Daiichi Sankyo, Arcturus Therapeutics, Sanofi, Ethris, Meiji Seika Pharma, Providence Therapeutics, Strand Therapeutics, and Orna Therapeutics. Respiratory products compete alongside emerging oncology, preparedness, and non-vaccine programs. Moderna's portfolio connects existing vaccination with potential therapeutic launches, while other developers pursue differentiated delivery and indication opportunities. Manufacturing scale, intellectual property, regulatory execution, and reimbursement evidence create substantial barriers. Commercial competition increasingly depends on a credible route from platform science to repeatable operations within each product's distinct clinical and distribution requirements.

Product Code: 15010

Table of Contents

Chapter 1. Research Methodology

  • 1.1 Research approach
  • 1.2 Quality commitments
    • 1.2.1 GMI AI policy & data integrity commitment
      • 1.2.1.1 Source consistency protocol
  • 1.3 Research trail & confidence scoring
    • 1.3.1 Research trail components
    • 1.3.2 Scoring components
  • 1.4 Data collection
    • 1.4.1 Partial list of primary sources
  • 1.5 Data mining sources
    • 1.5.1 Paid sources
      • 1.5.1.1 Sources, by region
  • 1.6 Base estimates and calculations
    • 1.6.1 Base year calculation
  • 1.7 Forecast model
    • 1.7.1 Quantified market impact analysis
      • 1.7.1.1 Mathematical impact of growth parameters on forecast
  • 1.8 Research transparency addendum
    • 1.8.1 Source attribution framework
    • 1.8.2 Quality assurance metrics
    • 1.8.3 Our commitment to trust

Chapter 2. Executive Summary

  • 2.1 Industry 360° synopsis
  • 2.2 Key market trends
    • 2.2.1 Product trends
    • 2.2.2 Application trends
    • 2.2.3 Age group trends
    • 2.2.4 End use trends
    • 2.2.5 Regional trends
  • 2.3 TAM Analysis, 2027-2035
    • 2.3.1 mRNA vaccines
    • 2.3.2 mRNA drugs
  • 2.4 CXO perspectives: strategic imperatives

Chapter 3. Industry Insights

  • 3.1 Industry ecosystem analysis
    • 3.1.1 Supplier landscape
    • 3.1.2 Profit margin
    • 3.1.3 Cost structure
    • 3.1.4 Value addition at each stage
    • 3.1.5 Factors affecting the value chain
    • 3.1.6 Disruptions
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Growing demand for rapid vaccine development platforms
      • 3.2.1.2 Strong commercial success of COVID-19 mRNA vaccines
      • 3.2.1.3 Increasing government support and pandemic preparedness initiatives
      • 3.2.1.4 Advancements in Lipid Nanoparticle (LNP) delivery technologies
      • 3.2.1.5 Expanding applications beyond COVID-19
    • 3.2.2 Restraints
      • 3.2.2.1 High manufacturing and cold-chain logistics costs
      • 3.2.2.2 Limited number of commercially approved products
      • 3.2.2.3 Complex regulatory and quality requirements
      • 3.2.2.4 Declining COVID-19 vaccination demand
    • 3.2.3 Market opportunities
      • 3.2.3.1 Expansion of personalized cancer vaccines
      • 3.2.3.2 Growing pipeline in infectious diseases beyond COVID-19
      • 3.2.3.3 Increasing investment and strategic partnerships
      • 3.2.3.4 Development of combination and multivalent therapies
    • 3.2.4 Market challenges
      • 3.2.4.1 Stability and storage challenges of mRNA molecules
      • 3.2.4.2 Immunogenicity and off-target effects in non-vaccine applications
      • 3.2.4.3 Competitive pressure from established traditional vaccine platforms
  • 3.3 Growth potential analysis
  • 3.4 Pricing analysis (Driven by Primary Research)
    • 3.4.1 Historical price trend analysis
    • 3.4.2 Pricing strategy by player type (Premium / Value / Cost-plus)
  • 3.5 Regulatory landscape (Driven by Primary Research)
    • 3.5.1 North America
      • 3.5.1.1 U.S.
      • 3.5.1.2 Canada
    • 3.5.2 Europe
    • 3.5.3 Asia Pacific
    • 3.5.4 Latin America
    • 3.5.5 Middle East and Africa
  • 3.6 Porter's analysis
  • 3.7 PESTEL analysis
  • 3.8 Trade data analysis (Based on Paid Database)
    • 3.8.1 Import/Export volume & value trends
    • 3.8.2 Key trade corridors & tariff impact
  • 3.9 Impact of AI and Gen AI on the market (Driven by Primary Research)
    • 3.9.1 AI-driven disruption of existing business models
    • 3.9.2 GenAI use cases & adoption roadmap by segment
    • 3.9.3 Risks, limitations & regulatory considerations
  • 3.10 Technology & innovation landscape
    • 3.10.1 Current technological trends
    • 3.10.2 Emerging technologies (Driven by Primary Research)
  • 3.11 Clinical trial / pipeline analysis (Driven by Primary Research)
    • 3.11.1 Vaccine products
    • 3.11.2 Non-vaccine products
  • 3.12 Patent / IP landscape (Driven by Primary Research)
  • 3.13 Medical infrastructure landscape
  • 3.14 Epidemiology / disease burden

Chapter 4. Competitive Landscape, 2025

  • 4.1 Introduction
  • 4.2 Company market share analysis
    • 4.2.1 By region
      • 4.2.1.1 North America
      • 4.2.1.2 Europe
      • 4.2.1.3 Asia Pacific
      • 4.2.1.4 Latin America
      • 4.2.1.5 Middle East and Africa
    • 4.2.2 Market concentration analysis
  • 4.3 Competitive analysis of major market players
  • 4.4 Competitive positioning matrix
  • 4.5 Key developments
    • 4.5.1 Mergers & acquisitions
    • 4.5.2 Partnerships & collaborations
    • 4.5.3 New product launches
    • 4.5.4 Expansion plans and funding
  • 4.6 Company tier benchmarking
    • 4.6.1 Tier classification criteria & qualifying thresholds
    • 4.6.2 Tier positioning matrix by revenue, geography & innovation

Chapter 5. Market Estimates and Forecast, By Product, 2022-2035 ($ Mn)

  • 5.1 Key trends
  • 5.2 Comirnaty
  • 5.3 Spikevax
  • 5.4 mRESVIA
  • 5.5 Other products

Chapter 6. Market Estimates and Forecast, By Application, 2022-2035 ($ Mn)

  • 6.1 Key trends
  • 6.2 COVID-19 prevention
  • 6.3 Respiratory syncytial virus (RSV) prevention

Chapter 7. Market Estimates and Forecast, By Age Group, 2022-2035 ($ Mn)

  • 7.1 Key trends
  • 7.2 Pediatric
  • 7.3 Adult
  • 7.4 Geriatric

Chapter 8. Market Estimates and Forecast, By End Use, 2022-2035 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospitals and clinics
  • 8.3 Government immunization programmes
  • 8.4 Other end users

Chapter 9. Market Estimates and Forecast, By Region, 2022-2035 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 India
    • 9.4.3 Japan
    • 9.4.4 Australia
    • 9.4.5 South Korea
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE

Chapter 10. Company Profiles

  • 10.1 Global players
    • 10.1.1 Pfizer
    • 10.1.2 BioNTech
    • 10.1.3 Moderna
  • 10.2 Pipeline players
    • 10.2.1 Daiichi Sankyo
    • 10.2.2 Ethris
    • 10.2.3 Meiji Seika Pharma
    • 10.2.4 Arcturus Therapeutics
    • 10.2.5 Sanofi
    • 10.2.6 Providence Therapeutics
    • 10.2.7 Strand Therapeutics
    • 10.2.8 Orna Therapeutics
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!